My watch list  


Systematic (IUPAC) name
CAS number 52757-95-6
ATC code V03AE02
PubChem 3085017
DrugBank APRD01226
Chemical data
Formula [(C3H7N)a+b.(C9H17N2O)c]m
where a+b:c = 9:1
Mol. mass variable
Pharmacokinetic data
Bioavailability nil
Metabolism nil
Half life n/a
Excretion faecal 100%
Therapeutic considerations
Pregnancy cat.

B3 (Australia)

Legal status

Schedule 4 (Australia)

Routes oral

Sevelamer (rINN) (pronounced /sɛˈvɛləmɚ/, /-mɪr/) is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.


Chemistry and pharmacology

Sevelamer is a copolymer of 2-(chloromethyl)oxirane (epichlorohydrin) and prop-2-en-1-amine. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphorus molecules through ionic and hydrogen bonding.

Clinical use


Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic renal failure (end stage renal disease).


Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.

Adverse effects

Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sevelamer". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE